Cargando…

Computational Analysis of Cytokine Release Following Bispecific T-Cell Engager Therapy: Applications of a Logic-Based Model

Bispecific T-cell engaging therapies harness the immune system to elicit an effective anticancer response. Modulating the immune activation avoiding potential adverse effects such as cytokine release syndrome (CRS) is a critical aspect to realizing the full potential of this therapy. The use of suit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Selvaggio, Gianluca, Parolo, Silvia, Bora, Pranami, Leonardelli, Lorena, Harrold, John, Mehta, Khamir, Rock, Dan A., Marchetti, Luca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957948/ https://www.ncbi.nlm.nih.gov/pubmed/35350575 http://dx.doi.org/10.3389/fonc.2022.818641

Ejemplares similares

A quantitative systems pharmacology approach to support mRNA vaccine development and optimization
por: Selvaggio, Gianluca, et al.
Publicado: (2021)

A QSP model of prostate cancer immunotherapy to identify effective combination therapies
por: Coletti, Roberta, et al.
Publicado: (2020)

Literature Mining and Mechanistic Graphical Modelling to Improve mRNA Vaccine Platforms
por: Leonardelli, Lorena, et al.
Publicado: (2021)

A Novel Hybrid Logic-ODE Modeling Approach to Overcome Knowledge Gaps
por: Selvaggio, Gianluca, et al.
Publicado: (2021)

A network-based approach to identify deregulated pathways and drug effects in metabolic syndrome
por: Misselbeck, Karla, et al.
Publicado: (2019)

A novel logical model of COVID-19 intracellular infection to support therapies development
por: Piretto, Elena, et al.
Publicado: (2022)

Reconstruction of the Cytokine Signaling in Lysosomal Storage Diseases by Literature Mining and Network Analysis
por: Parolo, Silvia, et al.
Publicado: (2021)

Single-cell-led drug repurposing for Alzheimer’s disease
por: Parolo, Silvia, et al.
Publicado: (2023)

A Modeling Framework to Characterize Cytokine Release upon T‐Cell–Engaging Bispecific Antibody Treatment: Methodology and Opportunities
por: Chen, Xiaoying, et al.
Publicado: (2019)

In Silico Logical Modelling to Uncover Cooperative Interactions in Cancer
por: Selvaggio, Gianluca, et al.
Publicado: (2021)

An age‐dependent mathematical model of neurofilament trafficking in healthy conditions
por: Paris, Alessio, et al.
Publicado: (2022)

Editorial: Bispecific Antibodies for T-Cell Based Immunotherapy
por: Santich, Brian H., et al.
Publicado: (2020)

Anti-CS1 × Anti-CD3 Bispecific Antibody (BiAb)-Armed Anti-CD3 Activated T Cells (CS1-BATs) Kill CS1(+) Myeloma Cells and Release Type-1 Cytokines
por: Lum, Lawrence G., et al.
Publicado: (2020)

Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies
por: Trinklein, Nathan D., et al.
Publicado: (2019)

Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
por: Leclercq-Cohen, Gabrielle, et al.
Publicado: (2023)

Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release
por: Aschmoneit, Nadine, et al.
Publicado: (2021)

Bispecific antibodies in multiple myeloma treatment: A journey in progress
por: Cho, Shih-Feng, et al.
Publicado: (2022)

A pediatric quantitative systems pharmacology model of neurofilament trafficking in spinal muscular atrophy treated with the antisense oligonucleotide nusinersen
por: Paris, Alessio, et al.
Publicado: (2022)

The landscape of bispecific T cell engager in cancer treatment
por: Zhou, Shujie, et al.
Publicado: (2021)

Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager
por: Xiao, Xinghui, et al.
Publicado: (2023)

Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy
por: Kobold, Sebastian, et al.
Publicado: (2018)

For whom the T cells troll? Bispecific T-cell engagers in glioblastoma
por: Singh, Kirit, et al.
Publicado: (2021)

Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release
por: Park, Jeong A, et al.
Publicado: (2021)

JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy
por: Leclercq, Gabrielle, et al.
Publicado: (2022)

Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning
por: Haber, Lauric, et al.
Publicado: (2021)

VHH-Based Bispecific Antibodies Targeting Cytokine Production
por: Nosenko, Maxim A., et al.
Publicado: (2017)

Controlling Cytokine Release Syndrome to Harness the Full Potential of CAR-Based Cellular Therapy
por: Thakar, Monica S., et al.
Publicado: (2020)

MEK Inhibitor Augments Antitumor Activity of B7-H3-Redirected Bispecific Antibody
por: Li, Hongjian, et al.
Publicado: (2020)

Therapeutic Bispecific T-Cell Engager Antibody Targeting the Transferrin Receptor
por: Fu, Mingpeng, et al.
Publicado: (2019)

Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies
por: Hoseini, Sayed Shahabuddin, et al.
Publicado: (2020)

Bispecific T-Cell Engagers Targeting Membrane-Bound IgE
por: Rodak, Aleksandra, et al.
Publicado: (2021)

Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies
por: Tian, Zheng, et al.
Publicado: (2021)

Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies
por: Poussin, Mathilde, et al.
Publicado: (2021)

Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges
por: Alhallak, Kinan, et al.
Publicado: (2021)

Combination therapies for the optimisation of Bispecific T-cell Engagers in cancer treatment
por: Zhu, Winston M, et al.
Publicado: (2023)

Simultaneous Multiple Interaction T-cell Engaging (SMITE) Bispecific Antibodies Overcome Bispecific T-cell Engager (BiTE) Resistance Via CD28 Co-Stimulation
por: Correnti, Colin E., et al.
Publicado: (2018)

Case Report: Chimeric Antigen Receptor T Cells Induced Late Severe Cytokine Release Syndrome
por: He, Jinping, et al.
Publicado: (2022)

Development of a Bispecific Antibody Targeting CD30 and CD137 on Hodgkin and Reed-Sternberg Cells
por: Rajendran, Sakthi, et al.
Publicado: (2019)

Integration of transcriptomic and genomic data suggests candidate mechanisms for APOE4-mediated pathogenic action in Alzheimer’s disease
por: Caberlotto, Laura, et al.
Publicado: (2016)

Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity
por: Sam, Johannes, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gqqn45e4tmj0nnthvc64e5um7d